NCT05908916View on ClinicalTrials.gov

Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

AtezoBev with combined radiotherapy

Atezolizumab (1200mg) and Bevacizumab (15mg/kg) are administered to patients once for each cycle with 3-week intervals, and additional radiotherapy (iGTV 50-60 Gy, CTV 40Gy, PTV 30Gy / 10Fx) for the mass or portal vein tumor thrombosis is performed before second cycle of AtezoBev.

Trial Locations (1)

Unknown

Severance hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER